Do analysts rate NKTX or AVTE?

Nkarta currently has a consensus price target of $10.75, indicating a potential upside of 336.99%. Given Nkarta's stronger consensus rating and higher possible upside, research analysts plainly believe Nkarta is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nkarta 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, NKTX or AVTE?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nkarta N/A N/A -$104.08M -$1.34 N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is NKTX or AVTE more profitable?

Nkarta's return on equity of -30.90% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Nkarta N/A -30.90% -24.20% Aerovate Therapeutics N/A -90.19% -77.47%

Which has preferable earnings and valuation, NVCT or NKTX?

Nuvectis Pharma is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvectis Pharma N/A N/A -$26.44M -$1.31 N/A Nkarta N/A N/A -$104.08M -$1.34 N/A

Is NVCT or NKTX more profitable?

Nkarta's return on equity of -30.90% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Nuvectis Pharma N/A -184.25% -105.24% Nkarta N/A -30.90% -24.20%

Does the media prefer NVCT or NKTX?

In the previous week, Nuvectis Pharma had 9 more articles in the media than Nkarta. MarketBeat recorded 18 mentions for Nuvectis Pharma and 9 mentions for Nkarta. Nuvectis Pharma's average media sentiment score of 0.30 beat Nkarta's score of 0.27 indicating that Nuvectis Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Nkarta 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, MPLT or NKTX?

Nkarta is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maplight Therapeutics N/A N/A -$161.15M -$40.99 N/A Nkarta N/A N/A -$104.08M -$1.34 N/A

Is MPLT or NKTX more profitable?

Maplight Therapeutics' return on equity of 0.00% beat Nkarta's return on equity. Company Net Margins Return on Equity Return on Assets Maplight Therapeutics N/A N/A N/A Nkarta N/A -30.90% -24.20%

Does the media prefer MPLT or NKTX?

In the previous week, Nkarta had 4 more articles in the media than Maplight Therapeutics. MarketBeat recorded 9 mentions for Nkarta and 5 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.55 beat Nkarta's score of 0.27 indicating that Maplight Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nkarta 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, NKTX or ALT?

Altimmune has higher revenue and earnings than Nkarta. Altimmune is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nkarta N/A N/A -$104.08M -$1.34 N/A Altimmune $40K 14,828.34 -$88.09M -$0.93 N/A

Is NKTX or ALT more profitable?

Nkarta has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Nkarta's return on equity of -30.90% beat Altimmune's return on equity. Company Net Margins Return on Equity Return on Assets Nkarta N/A -30.90% -24.20% Altimmune -214,860.98% -42.57% -35.57%

Does the media refer more to NKTX or ALT?

In the previous week, Nkarta had 4 more articles in the media than Altimmune. MarketBeat recorded 9 mentions for Nkarta and 5 mentions for Altimmune. Nkarta's average media sentiment score of 0.27 beat Altimmune's score of 0.15 indicating that Nkarta is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nkarta 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Altimmune 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is NKTX or STTK more profitable?

Nkarta's return on equity of -30.90% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Nkarta N/A -30.90% -24.20% Shattuck Labs N/A -60.73% -55.75%

Does the media favor NKTX or STTK?

In the previous week, Nkarta had 6 more articles in the media than Shattuck Labs. MarketBeat recorded 9 mentions for Nkarta and 3 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 0.90 beat Nkarta's score of 0.27 indicating that Shattuck Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nkarta 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Shattuck Labs 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Nkarta (NKTX) Competitors

$2.46 +0.05 (+2.07%)

As of 04:00 PM Eastern

Compare

NKTX vs. AVTE, NVCT, MPLT, ALT, and STTK

Should you buy Nkarta stock or one of its competitors? Nkarta's main competitors and comparable companies include Aerovate Therapeutics (AVTE), Nuvectis Pharma (NVCT), Maplight Therapeutics (MPLT), Altimmune (ALT), and Shattuck Labs (STTK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nkarta compare to Aerovate Therapeutics?

Nkarta (NASDAQ:NKTX) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Nkarta currently has a consensus price target of $10.75, indicating a potential upside of 336.99%. Given Nkarta's stronger consensus rating and higher possible upside, research analysts plainly believe Nkarta is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Nkarta had 9 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 9 mentions for Nkarta and 0 mentions for Aerovate Therapeutics. Nkarta's average media sentiment score of 0.27 beat Aerovate Therapeutics' score of 0.00 indicating that Nkarta is being referred to more favorably in the media.

Company	Overall Sentiment
Nkarta	Neutral
Aerovate Therapeutics	Neutral

Nkarta has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

Nkarta's return on equity of -30.90% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-30.90%	-24.20%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

80.5% of Nkarta shares are held by institutional investors. 9.8% of Nkarta shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Nkarta beats Aerovate Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Nkarta compare to Nuvectis Pharma?

Nuvectis Pharma (NASDAQ:NVCT) and Nkarta (NASDAQ:NKTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Nuvectis Pharma is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

In the previous week, Nuvectis Pharma had 9 more articles in the media than Nkarta. MarketBeat recorded 18 mentions for Nuvectis Pharma and 9 mentions for Nkarta. Nuvectis Pharma's average media sentiment score of 0.30 beat Nkarta's score of 0.27 indicating that Nuvectis Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Nkarta	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 28.6% of Nuvectis Pharma shares are owned by company insiders. Comparatively, 9.8% of Nkarta shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Nuvectis Pharma has a beta of -0.26, indicating that its stock price is 126% less volatile than the broader market. Comparatively, Nkarta has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Nkarta's return on equity of -30.90% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-184.25%	-105.24%
Nkarta	N/A	-30.90%	-24.20%

Nuvectis Pharma currently has a consensus target price of $35.00, indicating a potential upside of 85.38%. Nkarta has a consensus target price of $10.75, indicating a potential upside of 336.99%. Given Nkarta's stronger consensus rating and higher probable upside, analysts plainly believe Nkarta is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Nkarta beats Nuvectis Pharma on 7 of the 13 factors compared between the two stocks.

How does Nkarta compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Nkarta (NASDAQ:NKTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Maplight Therapeutics presently has a consensus price target of $31.17, suggesting a potential upside of 155.88%. Nkarta has a consensus price target of $10.75, suggesting a potential upside of 336.99%. Given Nkarta's higher possible upside, analysts clearly believe Nkarta is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.94
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

80.5% of Nkarta shares are held by institutional investors. 3.8% of Maplight Therapeutics shares are held by insiders. Comparatively, 9.8% of Nkarta shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Maplight Therapeutics' return on equity of 0.00% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Nkarta	N/A	-30.90%	-24.20%

Nkarta is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

In the previous week, Nkarta had 4 more articles in the media than Maplight Therapeutics. MarketBeat recorded 9 mentions for Nkarta and 5 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.55 beat Nkarta's score of 0.27 indicating that Maplight Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nkarta	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Maplight Therapeutics beats Nkarta on 7 of the 13 factors compared between the two stocks.

How does Nkarta compare to Altimmune?

Nkarta (NASDAQ:NKTX) and Altimmune (NASDAQ:ALT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

Nkarta has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Nkarta's return on equity of -30.90% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-30.90%	-24.20%
Altimmune	-214,860.98%	-42.57%	-35.57%

Altimmune has higher revenue and earnings than Nkarta. Altimmune is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A
Altimmune	$40K	14,828.34	-$88.09M	-$0.93	N/A

In the previous week, Nkarta had 4 more articles in the media than Altimmune. MarketBeat recorded 9 mentions for Nkarta and 5 mentions for Altimmune. Nkarta's average media sentiment score of 0.27 beat Altimmune's score of 0.15 indicating that Nkarta is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nkarta	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nkarta has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, Altimmune has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

Nkarta presently has a consensus target price of $10.75, suggesting a potential upside of 336.99%. Altimmune has a consensus target price of $15.71, suggesting a potential upside of 415.22%. Given Altimmune's higher probable upside, analysts plainly believe Altimmune is more favorable than Nkarta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Altimmune	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

80.5% of Nkarta shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 9.8% of Nkarta shares are owned by insiders. Comparatively, 1.6% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Nkarta beats Altimmune on 11 of the 16 factors compared between the two stocks.

How does Nkarta compare to Shattuck Labs?

Nkarta (NASDAQ:NKTX) and Shattuck Labs (NASDAQ:STTK) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

80.5% of Nkarta shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 9.8% of Nkarta shares are owned by company insiders. Comparatively, 8.8% of Shattuck Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Nkarta presently has a consensus target price of $10.75, indicating a potential upside of 336.99%. Shattuck Labs has a consensus target price of $12.63, indicating a potential upside of 76.82%. Given Nkarta's stronger consensus rating and higher probable upside, equities analysts plainly believe Nkarta is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

In the previous week, Nkarta had 6 more articles in the media than Shattuck Labs. MarketBeat recorded 9 mentions for Nkarta and 3 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 0.90 beat Nkarta's score of 0.27 indicating that Shattuck Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nkarta	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Shattuck Labs	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nkarta has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Shattuck Labs has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

Shattuck Labs has higher revenue and earnings than Nkarta. Shattuck Labs is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A
Shattuck Labs	$1M	547.50	-$48.81M	-$0.63	N/A

Nkarta's return on equity of -30.90% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-30.90%	-24.20%
Shattuck Labs	N/A	-60.73%	-55.75%

Summary

Nkarta beats Shattuck Labs on 9 of the 15 factors compared between the two stocks.

Get Nkarta News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NKTX vs. The Competition

Export

Metric	Nkarta	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$172.42M	$3.70B	$7.02B	$12.98B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-1.84	5.30	210.34	20.96
Price / Sales	N/A	1,255.26	588.78	86.31
Price / Cash	N/A	44.95	28.89	37.42
Price / Book	0.56	17.66	11.27	6.42
Net Income	-$104.08M	-$13.25M	$3.45B	$347.03M
7 Day Performance	14.42%	5.36%	3.56%	2.48%
1 Month Performance	-17.17%	-1.74%	-0.58%	-1.04%
1 Year Performance	24.24%	61.36%	77.52%	23.22%

Nkarta Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NKTX Nkarta	4.344 of 5 stars	$2.46 +2.1%	$10.75 +337.0%	+21.7%	$172.42M	N/A	N/A	140	News Coverage Earnings Report
AVTE Aerovate Therapeutics	N/A	$19.75 -1.3%	N/A	+193.2%	$572.45M	N/A	N/A	20	Gap Up High Trading Volume
NVCT Nuvectis Pharma	3.9242 of 5 stars	$21.60 +0.4%	$35.00 +62.0%	+215.8%	$570.83M	N/A	N/A	8	Earnings Report
MPLT Maplight Therapeutics	3.3979 of 5 stars	$12.55 -3.6%	$34.42 +174.2%	N/A	$554.89M	N/A	N/A	109	Analyst Downgrade Gap Down
ALT Altimmune	2.0975 of 5 stars	$3.00 +5.6%	$15.71 +423.8%	-10.7%	$552.31M	$40K	N/A	50	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NKTX) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nkarta (NKTX) Competitors

NKTX vs. AVTE, NVCT, MPLT, ALT, and STTK

How does Nkarta compare to Aerovate Therapeutics?

Summary

How does Nkarta compare to Nuvectis Pharma?

Summary

How does Nkarta compare to Maplight Therapeutics?

Summary

How does Nkarta compare to Altimmune?

Summary

How does Nkarta compare to Shattuck Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX vs. The Competition

Nkarta Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nkarta (NKTX) Competitors

NKTX vs. AVTE, NVCT, MPLT, ALT, and STTK

How does Nkarta compare to Aerovate Therapeutics?

Which has better earnings and valuation, NKTX or AVTE?

Do analysts rate NKTX or AVTE?

Does the media refer more to NKTX or AVTE?

Which has more volatility and risk, NKTX or AVTE?

Is NKTX or AVTE more profitable?

Do institutionals & insiders have more ownership in NKTX or AVTE?

Summary

How does Nkarta compare to Nuvectis Pharma?

Which has preferable earnings and valuation, NVCT or NKTX?

Does the media prefer NVCT or NKTX?

Do institutionals and insiders have more ownership in NVCT or NKTX?

Which has more risk and volatility, NVCT or NKTX?

Is NVCT or NKTX more profitable?

Do analysts prefer NVCT or NKTX?

Summary

How does Nkarta compare to Maplight Therapeutics?

Do analysts rate MPLT or NKTX?

Do insiders and institutionals have more ownership in MPLT or NKTX?

Is MPLT or NKTX more profitable?

Which has better valuation & earnings, MPLT or NKTX?

Does the media prefer MPLT or NKTX?

Summary

How does Nkarta compare to Altimmune?

Is NKTX or ALT more profitable?

Which has preferable valuation & earnings, NKTX or ALT?

Does the media refer more to NKTX or ALT?

Which has more risk & volatility, NKTX or ALT?

Do analysts prefer NKTX or ALT?

Do institutionals & insiders hold more shares of NKTX or ALT?

Summary

How does Nkarta compare to Shattuck Labs?

Do insiders and institutionals believe in NKTX or STTK?

Do analysts recommend NKTX or STTK?

Does the media favor NKTX or STTK?

Which has more risk & volatility, NKTX or STTK?

Which has stronger earnings and valuation, NKTX or STTK?

Is NKTX or STTK more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX vs. The Competition

Nkarta Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools